Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Status:
Completed
Trial end date:
2019-06-22
Target enrollment:
Participant gender:
Summary
The sponsor raise the hypothesis that inhibition of immune PD-1+/- CTLA-4 check-point(s)
would delay tumor progression in patients with unresectable MPM, experiencing disease
progression after one or two lines of chemotherapy including at least first-line with
pemetrexed and platinum, without altering significantly the quality of life of patients.
Phase:
Phase 2
Details
Lead Sponsor:
Intergroupe Francophone de Cancerologie Thoracique